Summary by Futu AI
Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has announced an offering of up to 1,886,792 shares of common stock, along with Series A-1 and Series A-2 Common Warrants to purchase additional shares. The company is also offering Pre-Funded Warrants to certain investors as an alternative to common stock, which would result in ownership exceeding 4.99% or 9.99% of outstanding shares post-offering. The event is planned with A.G.P./Alliance Global Partners acting as the sole Placement Agent on a reasonable best-efforts basis. The offering is expected to close within two business days following its commencement, with the exact date of the offering and the closing date yet to be determined. The proceeds from the offering are intended...Show More